Inhibiting an overabundant enzyme saved a key component of a brain signaling pathway that is vital for motor control in a ...

A group of 53 biotech leaders are expressing their support for mifepristone in a letter to the Food and Drug Administration, ...

AN Venture Partners has closed its first fund, a $200 million vault for biotechs worldwide, with particular emphasis on ...

The pulsed field ablation developer Kardium has collected $250 million in funding to gear up for the commercial expansion of ...

On Wednesday, Biokin reported (PDF) positive topline results from a phase 3 trial of the ADC. The study enrolled patients ...

After claiming an FDA approval last year, Intuitive has obtained a greenlight in Europe for its latest surgical robot, the da ...

Vyne Therapeutics has given up hopes of resuming a plaque psoriasis trial for its BET inhibitor placed on hold by the FDA, ...

Even the CEOs of Big Pharmas have come under fire. Activist investor Starboard Value has made no secret of its criticism of Pfizer CEO Albert Bourla’s track record, while GSK CEO Emma Walmsley fought ...

A drug candidate Organon hailed as perhaps its “biggest potential opportunity” has flunked a phase 2 trial, prompting the company to end clinical development of the endometriosis prospect.

Storied Japanese pharma Shionogi is upping its arsenal in the fight against antibiotic resistance. | Storied Japanese pharma ...

Catalio Capital Management has closed its fourth venture fund with more than $400 million that will be used in part to launch ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...